Walleye Capital’s Cardlytics CDLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-1,075
Closed -$12.4K 4454
2025
Q4
$12.4K Buy
+1,075
New +$16.6K ﹤0.01% 4288
2025
Q2
Sell
-203
Closed -$3.7K 4550
2025
Q1
$3.7K Sell
203
-4,047
-95% -$116K ﹤0.01% 4115
2024
Q4
$158K Buy
4,250
+2,352
+124% +$90K ﹤0.01% 3902
2024
Q3
$60.7K Buy
1,898
+677
+55% +$37.6K ﹤0.01% 4575
2024
Q2
$100K Sell
1,221
-3,550
-74% -$384K ﹤0.01% 4715
2024
Q1
$691K Buy
+4,771
New +$403K ﹤0.01% 2923
2023
Q3
Sell
-2,730
Closed -$173K 4915
2023
Q2
$173K Sell
2,730
-19,824
-88% -$1.2M ﹤0.01% 3165
2023
Q1
$766K Buy
22,554
+18,122
+409% +$947K 0.01% 1358
2022
Q4
$256K Buy
+4,432
New +$274K ﹤0.01% 1888
2022
Q2
Sell
-612
Closed -$336K 2390
2022
Q1
$336K Buy
+612
New +$370K 0.01% 1241
2020
Q1
Sell
-241
Closed -$151K 1012
2019
Q4
$151K Buy
+241
New +$118K 0.01% 1230

Other funds holding CDLX

Walleye Capital's CDLX Position: Q1 2026 in Review

Walleye Capital sold out of Cardlytics (CDLX) in Q1 2026, closing a stake of 1,075 shares — an estimated $12.4K sold.

Walleye Capital first reported a position in CDLX in Q4 2019 and held it in 11 quarters. The position peaked at $766K in Q1 2023. 58 funds tracked by Wall St. Rank hold CDLX as of Q1 2026.

  • Walleye Capital reported no remaining Cardlytics position as of Q1 2026 after selling out during the quarter.
  • Walleye Capital sold 1,075 Cardlytics shares in Q1 2026, an estimated $12.4K.
  • Walleye Capital first reported a position in Cardlytics in Q4 2019 and held it in 11 quarters.
  • Walleye Capital's Cardlytics position peaked at $766K in Q1 2023.
  • 58 funds tracked by Wall St. Rank held Cardlytics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.